Answers are grounded in this paper and cite their sources.
Prospective cohort study assesses responsiveness of the PHASE-20 tool in tracking medicine-related symptom changes, indicating its utility for clinical monitoring.
Introduction Monitoring patient-reported symptoms over time may support early detection of medicine-related harms. The Pharmacotherapeutic Symptom Evaluation-20–Australian version (PHASE-20–Australian version) is an 11-point rating scale designed for longitudinal monitoring of medicine-related symptoms; however, its responsiveness and minimum important change (MIC) have not been established. Aim To evaluate the responsiveness and MIC of the PHASE-20–Australian version for monitoring changes in medicine-related symptoms over time. Method A prospective cohort study was conducted among Australian adults (≥ 18 years) taking medications. Participants completed the PHASE-20–Australian version at baseline and follow-up and reported perceived symptom changes using the Global Rating Scale (GRS) at follow-up. Responsiveness was assessed by correlating score changes with the GRS and calculating the area under the receiver operating characteristic (ROC) curve (AUC). MIC was estimated using ROC anchor-based and 0.5 standard deviation (SD) distribution-based methods and then compared with the Smallest Detectable Change (SDC). Results Among 102 participants, 52% were aged ≥ 60 years and 65.7% were female. Strong correlations were observed for overall score changes ( rho = 0.815) with the GRS as well as for 84.2% of individual symptoms ( rho = 0.701–0.897). The tool demonstrated good to strong discriminative ability (AUC = 0.739–0.975 for improvement; 0.764–0.977 for deterioration), with sensitivity and specificity ≥ 0.75 for 16 symptoms. The MIC values ranged from 0.5 to 1.5 using the ROC method and 0.9–1.8 using the 0.5 SD approach. The estimated MIC values exceeded the SDC for 84.2% of symptoms. Limited responsiveness ( rho < 0.7, AUC < 0.7) and MIC values below the SDC were noted for forgetful, swollen legs/ankles and frequent urination/incontinent of urine. Conclusion The PHASE-20–Australian version is responsive for most symptoms, with a clinically meaningful change of approximately 2.0 points on a 0–10 scale. The estimated MIC is applicable at the individual level, although caution is needed for symptoms with an MIC below the SDC.
No takes yet. Share an insight, caveat, or question.
Mekuria et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: